title: Penetration of vancomycin into epithelial lining fluid in healthy volunteers.
abstract: Although vancomycin is often regarded as an agent that concentrates poorly in the lower respiratory tract, as determined from concentrations in epithelial lining fluid (ELF), few data are available. This study sought to determine the profile of vancomycin exposure in the ELF relative to plasma. Population modeling and Monte Carlo simulation were employed to estimate the penetration of vancomycin into ELF. Plasma and ELF pharmacokinetic (PK) data were obtained from 10 healthy volunteers. Concentration-time profiles in plasma and ELF were simultaneously modeled using a three-compartment model with zero-order infusion and first-order elimination and transfer using the big nonparametric adaptive grid (BigNPAG) program. Monte Carlo simulation with 9,999 subjects was performed to calculate the ELF/plasma penetration ratios by estimating the area under the concentration-time curve (AUC) in ELF (AUC(ELF)) and plasma (AUC(plasma)) after a single simulated 1,000-mg dose. The mean (standard deviation) AUC(ELF)/AUC(plasma) penetration ratio was 0.675 (0.677), and the 25th, 50th, and 75th percentile penetration ratios were 0.265, 0.474, and 0.842, respectively. Our results indicate that vancomycin penetrates ELF at approximately 50% of plasma levels. To properly judge the adequacy of current doses and schedules employed in practice, future studies are needed to delineate the PK/PD (pharmacodynamics) target for vancomycin in ELF. If the PK/PD target in ELF is found to be consistent with the currently proposed target of an AUC/MIC of ≥400, suboptimal probability of target attainment would be expected when vancomycin is utilized for pneumonias due to MRSA (methicillin-resistant Staphylococcus aureus) with MICs in excess of 1 mg/liter.
authors.affiliation: Albany College of Pharmacy, Pharmacy Practice Department, Albany, New York 12208, USA. thomas.lodise@acphs.edu
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Lodise
authors.forename: George L
authors.initials: GL
authors.lastname: Drusano
authors.forename: Jill M
authors.initials: JM
authors.lastname: Butterfield
authors.forename: Joshua
authors.initials: J
authors.lastname: Scoville
authors.forename: Mark
authors.initials: M
authors.lastname: Gotfried
authors.forename: Keith A
authors.initials: KA
authors.lastname: Rodvold
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry* / Q000382:microbiology; D001999:Bronchoscopy; D004848:Epithelium / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests / Q000706:statistics & numerical data; D008954:Models, Biological; D009010:Monte Carlo Method; D014640:Vancomycin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin